Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Dihydroartemisinin (DHA) and artesunate (ARS), two artemisinin derivatives, have efficacious anticancer activities against human hepatocarcinoma (HCC) cells. This study aims to study the anticancer action of the combination treatment of DHA/ARS and farnesylthiosalicylic acid (FTS), a Ras inhibitor,...
Main Authors: | Liping Wu, Yilin Pang, Guiqi Qin, Gaina Xi, Shengnan Wu, Xiaoping Wang, Tongsheng Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5300221?pdf=render |
Similar Items
-
Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination
by: Yuang Chen, et al.
Published: (2021-12-01) -
Neuroprotective Effect of S-trans, Trans-farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer’s Disease
by: Wang X, et al.
Published: (2019-11-01) -
The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
by: Yoram Nevo, et al.
Published: (2011-01-01) -
Synthesis and Anti-Hepatocarcinoma Effect of Amino Acid Derivatives of Pyxinol and Ocotillol
by: Ying Zhang, et al.
Published: (2021-02-01) -
Hepatocarcinoma
by: Iván Nieto, et al.
Published: (2007-12-01)